0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Two Superb Vaccines Against Hepatitis B in Mexican Standoff

Francis E. André, MB, BS, FRCPath
JAMA. 1988;259(16):2402-2403. doi:10.1001/jama.1988.03720160024018.
Text Size: A A A
Published online

To the Editor.  —In response to an editorial1 that criticized the choice of 10 μg of yeast-derived hepatitis B surface antigen (HBsAg) as the dose for Recombivax-HB, Drs Gerety and Ellis2 seek to justify the decision to use a lower dose of HBsAg than the 20 μg present in the plasma-derived Heptavax-B vaccine. They minimize the quantitative difference that has been clearly demonstrated3 in the immune response to yeast-derived and plasma-derived hepatitis B vaccines manufactured by Merck Sharp & Dohme. In support of their argument, Drs Gerety and Ellis make reference to the published abstract4 of a presentation that I made at the recent International Symposium on Viral Hepatitis and Liver Disease and state that the "article indicates that therapy with either 10 μg of Recombivax-HB or 20 μg of another yeast-derived vaccine produces comparable antibody response."The fact is, the abstract and my presentation gave

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();